Janus Henderson Investors US’s BioMarin Pharmaceuticals BMRN Stock Holding History

Janus Henderson Investors US’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1.36M	Sell	15,476 -12,800	-45%	-$1.14M	﹤0.01%	964
2016 Q4	$2.34M	Buy	28,276 +6,276	+29%	+$540K	﹤0.01%	941
2016 Q3	$2.04M	Sell	22,000 -1,800	-8%	-$169K	﹤0.01%	952
2016 Q2	$1.85M	Sell	23,800 -29,500	-55%	-$2.51M	﹤0.01%	927
2016 Q1	$4.4M	Sell	53,300 -389,600	-88%	-$31.7M	﹤0.01%	794
2015 Q4	$46.4M	Sell	442,900 -160,900	-27%	-$16.8M	0.04%	448
2015 Q3	$63.6M	Buy	603,800 +124,469	+26%	+$16.6M	0.06%	368
2015 Q2	$65.6M	Buy	479,331 +205,731	+75%	+$25.5M	0.05%	394
2015 Q1	$34.1M	Buy	273,600 +266,000	+3,500%	+$28.2M	0.03%	526
2014 Q4	$687K	Buy	7,600 +4,400	+138%	+$366K	﹤0.01%	1001
2014 Q3	$231K	Buy	+3,200	New	+$210K	﹤0.01%	1083
2014 Q2	–	Sell	-376,706	Closed	-$25.7M	–	1093
2014 Q1	$25.7M	Sell	376,706 -314,556	-46%	-$23.2M	0.02%	518
2013 Q4	$48.6M	Sell	691,262 -60,917	-8%	-$4.14M	0.05%	397
2013 Q3	$54.3M	Sell	752,179 -862,010	-53%	-$57.3M	0.05%	353
2013 Q2	$90.1M	Buy	+1,614,189	New	+$101M	0.09%	249

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Investors US's BMRN Position: Q1 2017 in Review

Janus Henderson Investors US reduced its BioMarin Pharmaceuticals (BMRN) stake by 45% in Q1 2017, selling an estimated $1.14M and leaving 15,476 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #964.

Janus Henderson Investors US first reported a position in BMRN in Q2 2013 and has held it in 15 quarters since. The position peaked at $90.1M in Q2 2013. 418 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

Janus Henderson Investors US held 15,476 shares of BioMarin Pharmaceuticals worth $1.36M as of Q1 2017.
Janus Henderson Investors US sold 12,800 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $1.14M.
BioMarin Pharmaceuticals made up ﹤0.01% of Janus Henderson Investors US's portfolio in Q1 2017, its #964 holding.
Janus Henderson Investors US first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
Janus Henderson Investors US's BioMarin Pharmaceuticals position peaked at $90.1M in Q2 2013.
418 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.